Detail akcie Acurx Pharm Rg online

Business Summary: Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Acurx Pharmaceuticals Inc revenues was not reported. Net loss decreased 44% to $6.4M. Lower net loss reflects Research and Development decrease of 66% to $1.6M (expense), General and Administrative decrease of 27% to $4.9M (expense), Interest Income increase from $6K to $59K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$14.32 to -$5.26.